SEPTInvestingStart Free

QNCX 10-Q: SEC filing

IRulya Therapeutics Inc.

Filed with the SEC on · accession 0001193125-26-460562

QNCX filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

IRulya Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting financial results and corporate developments including an acquisition of Orphai Therapeutics and equity financings.

For details, click here →How to read a 10-Q →

Key details

FilerIRulya Therapeutics Inc.
Acquired subsidiaryOrphai Therapeutics

✦ Ask GOAX AI about this filing — what it means for QNCX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for QNCX?

Click here

Frequently asked questions

What did QNCX file with the SEC on Nov 13, 2026?

QNCX filed a 10-Q (SEC filing). IRulya Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting financial results and corporate developments including an acquisition of Orphai Therapeutics and equity financings.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other QNCX SEC filings

Get alerts when QNCX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
QNCX overviewQNCX analysisQNCX newsLatest SEC filings